Fortress Biotech Faces Investor Concerns Amid Checkpoint Sale Fortress Biotech, Checkpoint’s controlling shareholder, will benefit from royalties under its sale to Sun Pharma, raising questions about potential conflicts. Despite Checkpoint’s financial struggles, including a $27.3 million loss, the deal offers shareholders a 66% premium on stock value, contingent on regulatory approval.34